Leerink Partners Assumes Zentalis Pharmaceuticals at Outperform, Raises Price Target to $8

Benzinga Newsdesk www.benzinga.com Positive 90.2%

Neg 0% Neu 0% Pos 90.2%

Leerink Partners analyst Asthika Goonewardene assumes Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Outperform rating and raises Price Target to $8.